核心蛋白聚糖对膀胱癌细胞增殖、迁移及侵袭的影响

doi:10.3760/cma.j.cn371439-20201007-00064

摘要/Abstract

摘要：

目的探讨核心蛋白聚糖(DCN)对膀胱癌细胞增殖、迁移及其侵袭的影响。方法以膀胱癌T24细胞株为研究对象,利用MTT法检测24、48、72、96 h不同浓度(0、5、10、20、30、40、50 mg/L)DCN对T24细胞增殖的抑制作用,流式细胞仪分析DCN对T24细胞周期及凋亡的影响,MTT法、Transwell细胞迁移和细胞侵袭实验分别检测DCN对T24细胞的黏附、迁移及侵袭的影响,ELISA及蛋白质印迹法分别检测DCN对TGF-β1和P21蛋白表达的影响。结果用浓度为0、5、10、20、30、40、50 mg/L DCN处理T24细胞,在24、48、72、96 h时细胞增殖活力差异均具有统计学意义(F=168.64,P<0.001;F=165.81,P<0.001;F=291.02,P<0.001;F=148.93,P<0.001);用0、5、10、20、30、40和50 mg/L浓度的DCN处理T24细胞72 h时,细胞增殖活力分别为(60.71±3.03)%、(40.82±2.09)%、(37.24±1.63)%、(25.65±2.55)%、(23.00±2.67)%、(10.78±1.17)%、(11.04±0.96)%,差异具有统计学意义,40 mg/L浓度时增殖活力达到最低水平,对细胞增殖的抑制作用最强。40、50 mg/L浓度时G₁期细胞达到高峰值,S期达最低,整个处理过程G₂期始终保持不变。0、5、10、20、30、40、50 mg/L浓度DCN作用72 h时的细胞凋亡率分别为(12.18±1.17)%、(21.24±1.05)%、(19.80±1.20)%、(26.52±1.40)%、(30.86±1.40)%、(52.99±1.22)%、(43.04±2.16)%,差异具有统计学意义(F=178.54,P<0.001);5、10、20、30、40、50 mg/L浓度DCN凋亡率与0 mg/L浓度DCN相比,差异均具有统计学意义(均P<0.001)。DCN作用于T24细胞72 h时,0、40 mg/L浓度时的细胞黏附率分别为(37.14±1.35)%、(59.86±1.95)%,差异具有统计学意义(t=25.25,P<0.001);迁移细胞数分别为53.86±3.18、12.86±1.35,差异具有统计学意义(t=31.36,P<0.001)。DCN作用于T24细胞48 h时,0、40 mg/L浓度时的侵袭数分别为235.14±3.44、160.86±3.13,差异具有统计学意义(t=2.27,P<0.001)。当T24细胞被DCN处理72 h 后,0、5、10、20、30、40、50 mg/L浓度时的TGF-β1相对表达量分别为85.67±3.35、45.51±1.19、49.93±4.15、47.64±3.53、46.05±3.18、25.54±2.25、33.44±4.05,差异具有统计学意义(F=324.58,P<0.001),与0 mg/L相比,5、10、20、30、40、50 mg/L浓度均对TGF-β1的表达有明显的抑制作用(均P<0.001);与0 mg/L浓度相比,P21蛋白经40 mg/L DCN处理72 h后上调。结论 DCN在体外能够抑制T24细胞增殖,诱导其凋亡,并具有抗T24细胞转移的作用。

关键词: 膀胱肿瘤, 细胞运动, 肿瘤浸润, 核心蛋白聚糖

Abstract:

Objective To investigate the effects of decorin (DCN) on the proliferation, migration and invasion of bladder cancer cells. Methods Bladder cancer T24 cell line was used as the research object. MTT assay was used to detect the inhibitory effect of DCN at different concentrations (0, 5, 10, 20, 30, 40, 50 mg/L) on T24 cell proliferation at 24, 48, 72 and 96 h. The effects of DCN on T24 cell cycle and apoptosis were analyzed by flow cytometry. MTT assay, Transwell migration and invasion experiments were used to detect the effects of DCN on the adhesion, migration and invasion ability of T24 cells. The effects of DCN on TGF-β1 and P21 protein expression were detected by ELISA and Western blotting. Results T24 cells were treated with 0, 5, 10, 20, 30, 40 and 50 mg/L DCN at 24, 48, 72 and 96 h, and there were statistically significant diffe-rences in cell proliferation activity (F=168.64, P<0.001; F=165.81, P<0.001; F=291.02, P<0.001; F=148.93, P<0.001). T24 cells were treated with 0, 5, 10, 20, 30, 40 and 50 mg/L DCN for 72 h, and the cell proliferation activities were (60.71±3.03)%, (40.82±2.09)%, (37.24±1.63)%, (25.65±2.55)%, (23.00±2.67)%, (10.78±1.17)%, (11.04±0.96)%, respectively, and there was a statistically significant difference. At the concentration of 40 mg/L, the proliferation activity reached the lowest level, and the inhibitory effect on cell proliferation was the strongest. At concentrations of 40 and 50 mg/L, the cells in G₁ phase reached the peak value, while the cells in S phase reached the lowest value, and the cells in G₂ phase remained unchanged throughout the treatment process. T24 cells were treated with 0, 5, 10, 20, 30, 40 and 50 mg/L DCN for 72 h, and the apoptosis rates of cells were (12.18±1.17)%, (21.24±1.05)%, (19.80±1.20)%, (26.52±1.40)%, (30.86±1.40)%, (52.99±1.22)%, (43.04±2.16)%, respectively, and there was a statistically significant difference (F=178.54, P<0.001). The differences between 5, 10, 20, 30, 40, 50 mg/L DCN and 0 mg/L DCN were all statistically significant (all P<0.001). When T24 cells were treated with 0, 40 mg/L DCN for 72 h, the cell adhesion rates were (37.14±1.35)% and (59.86±1.95)%, the numbers of migrated cells were 53.86±3.18 and 12.86±1.35, and there were statistically significant differences (t=25.25, P<0.001; t=31.36, P<0.001). When DCN was applied to T24 cells for 48 h, the numbers of invasion at 0, 40 mg/L were 235.14±3.44 and 160.86±3.13, and there was a statistically significant difference (t=2.27, P<0.001). When T24 cells were treated with 0, 5, 10, 20, 30, 40 and 50 mg/L DCN for 72 h, the relative expression levels of TGF-β1 were 85.67±3.35, 45.51±1.19, 49.93±4.15, 47.64±3.53, 46.05±3.18, 25.54±2.25, 33.44±4.05, and there was a statistically significant difference (F=324.58, P<0.001). Compared with 0 mg/L DCN, 5, 10, 20, 30, 40 and 50 mg/L DCN could significantly inhibited the expression of TGF-β1 (all P<0.001). Compared with 0 mg/L DCN, P21 protein was upregulated 72 h after treatment with 40 mg/L DCN. Conclusion DCN can inhibit proliferation and induce apoptosis of T24 cells in vitro, and has the effect of anti-metastasis of T24 cells.

Key words: Urinary bladder neoplasms, Cell movement, Neoplasm invasiveness, Decorin

王子宜, 陈鸿杰, 杨宁刚, 张骏, 张向军, 于新宁, 马忠义, 戴恩来. 核心蛋白聚糖对膀胱癌细胞增殖、迁移及侵袭的影响[J]. 国际肿瘤学杂志, 2021, 48(6): 335-340.

Wang Ziyi, Chen Hongjie, Yang Ninggang, Zhang Jun, Zhang Xiangjun, Yu Xinning, Ma Zhongyi, Dai Enlai. Effects of decorin on proliferation, migration and invasion of bladder cancer cells[J]. Journal of International Oncology, 2021, 48(6): 335-340.

图/表 7

表1

表2

图1

图2

图3

图4

图5

参考文献 13

[1]	黄健 . 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M]. 北京: 科学出版社, 2020: 325.
[2]	Hong X, Yang Z, Wang M, et al. Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with Ⅰ-ⅢA non-small cell lung cancer[J]. Tumour Biol, 2016,37:16029-16038. DOI: 10.1007/s13277-016-5431-1. doi: 10.1007/s13277-016-5431-1
[3]	Reszegi A, Horváth Z, Karászi K, et al. The protective role of decorin in hepatic metastasis of colorectal carcinoma[J]. Biomolecules, 2020,10(8):1199-1215. DOI: 10.3390/biom10081199. doi: 10.3390/biom10081199
[4]	Liu YF, Wang X, Wang Z, et al. Decorin inhibits the proliferation of HepG2 cells by elevating the expression of transforming growth factor-β receptor II[J]. Exp Ther Med, 2016,12(4):2191-2195. DOI: 10.3892/etm.2016.3572. doi: 10.3892/etm.2016.3572
[5]	Zhao H, Wang H, Kong F, et al. Oncolytic adenovirus rAd. DCN inhibits breast tumor growth and lung metastasis in an immune-competent orthotopic xenograft model[J]. Hum Gene Ther, 2019,30(2):197-210. DOI: 10.1089/hum.2018.055. doi: 10.1089/hum.2018.055
[6]	Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer[J]. Med Sci (Basel), 2020,8(1):15-26. DOI: 10.3390/medsci8010015.
[7]	Appunni S, Anand V, Khandelwal M, et al. Small leucine rich proteoglycans (decorin, biglycan and lumican) in cancer[J]. Clin Chim Acta, 2019,491:1-7. DOI: 10.1016/j.cca.2019.01.003. doi: 10.1016/j.cca.2019.01.003
[8]	Zhang W, Ge Y, Cheng Q, et al. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment[J]. Oncotarge, 2018,9(4):5480-5491. DOI: 10.18632/oncotarget.23869. doi: 10.18632/oncotarget.v9i4
[9]	Horváth Z, Reszegi A, Szilák L, et al. Tumor-specific inhibitory action of decorin on different hepatoma cell lines[J]. Cell Signal, 2019,62:109354-109363. DOI: 10.1016/j.cellsig.2019.109354. doi: 10.1016/j.cellsig.2019.109354
[10]	Mao L, Yang J, Yue J, et al. Decorin deficiency promotes epithelial-mesenchymal transition and colon cancer metastasis[J]. Matrix Biol, 2021,95:1-4. DOI: 10.1016/j.matbio.2020.10.001. doi: 10.1016/j.matbio.2020.10.001
[11]	Tanaka T, Terai Y, Ohmichi M. Association of matrix metalloproteinase-9 and decorin expression with the infiltration of cervical cancer[J]. Oncol Lett, 2019,17(1):1306-1312. DOI: 10.3892/ol.2018.9713.
[12]	Gao Y, Ma HY, Xu QY, et al. Mechanism of decorin protein inhi-biting inrasion and metastasis of non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci, 2019,23(4):1520-1527. DOI: 10.26355/eurrev_201902_17110. doi: 17110 pmid: 30840274
[13]	Fang C, He W, Xu T, et al. Upregulation of lncRNA DGCR5 correlates with better prognosis and inhibits bladder cancer progression via transcriptionally facilitating P21 expression[J]. J Cell Physio, 2019,234(5):6254-6262. DOI: 10.1002/jcp.27356. doi: 10.1002/jcp.27356

DCN浓度(mg/L)	24 h	48 h	72 h	96 h
0	59.70±2.10	60.47±1.81	60.71±3.03^a	59.47±1.81
5	39.00±1.43	52.73±2.27	40.82±2.09^a	52.20±2.20
10	36.09±1.93	44.99±3.00	37.24±1.63^a	45.49±2.38
20	28.03±1.91	39.83±2.11	25.65±2.55^a	40.71±2.92
30	24.18±1.99	31.41±2.46	23.00±2.67^a	32.81±2.24
40	22.35±1.59	26.28±1.84	10.78±1.17	27.49±1.28
50	22.19±0.93	26.46±2.31	11.04±0.96	27.01±1.84
F值	168.64	165.81	291.02	148.93
P值	<0.001	<0.001	<0.001	<0.001

DCN浓度(mg/L)	细胞周期停滞比率			细胞凋亡率
DCN浓度(mg/L)	G₁期	S期	G₂期	细胞凋亡率
0	38.86±0.63^ab	60.87±0.67^ab	1.76±0.59	12.18±1.17^ab
5	37.12±0.75^ab	60.83±0.84^ab	2.06±1.59	21.24±1.05^abc
10	36.61±0.40^ab	61.73±2.09^ab	1.67±1.69	19.80±1.20^abc
20	36.23±1.39^ab	60.34±1.39^ab	2.95±0.69	26.52±1.40^abc
30	38.73±2.10^ab	59.13±1.43^ab	2.15±0.67	30.86±1.40^abc
40	69.79±0.62	26.74±0.67	3.48±1.29	52.99±1.22^b
50	71.05±1.18	27.19±1.67	1.77±0.14	43.04±2.16
F值	240.17	238.66	1.66	178.54
P值	<0.001	<0.001	0.530	<0.001

[1]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[2]	石雨, 陈曦, 许梦琪, 张滢滢, 冀洪海, 蒋英英. 沉默PSIP1基因对口腔鳞状细胞癌细胞迁移及侵袭的影响[J]. 国际肿瘤学杂志, 2022, 49(3): 129-133.
[3]	来比江·吾斯曼, 曹博威, 张文斌, 高华. 外源性AGR2对结肠癌细胞增殖及侵袭能力的影响[J]. 国际肿瘤学杂志, 2022, 49(2): 73-78.
[4]	徐希, 高红亮, 刘翔, 张振声, 许传亮. 肿瘤微环境pH值差异与膀胱癌的相关性[J]. 国际肿瘤学杂志, 2022, 49(11): 696-609.
[5]	蒋梦婷, 王家淳, 宗静. 抑制NFAT5对肺腺癌细胞增殖、侵袭、迁移及凋亡能力的影响[J]. 国际肿瘤学杂志, 2021, 48(6): 321-327.
[6]	马秀珍, 卢艳, 赵冰冰, 邱宏聪, 徐勋, 韦敏. 岗松总黄酮对宫颈癌SiHa细胞迁移、侵袭及凋亡的影响[J]. 国际肿瘤学杂志, 2021, 48(4): 206-211.
[7]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[8]	赵丽丽, 赵文文, 冯青青, 赵文飞, 张雪, 井文君, 魏红梅. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710.
[9]	熊琳, 张修云, 张小余, 黎越, 徐细明. IWR-1-endo通过抑制Wnt通路影响肝癌细胞的迁移和增殖[J]. 国际肿瘤学杂志, 2021, 48(12): 711-715.
[10]	李哲丰, 李洁, 赵晓婷, 岳文涛. GLDC通过PI3K/Akt/mTOR通路调控卵巢癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2021, 48(12): 716-722.
[11]	黄锐1, 伍刚1, 许健1, 郑波1, 黄凌远2, 钟振东1. miR-193b表达上调对HBV阳性肝癌细胞的影响[J]. 国际肿瘤学杂志, 2019, 46(2): 77-81.
[12]	陈炯玉, 庄轶轩, 庄珊珊, 彭琳. 蛇床子素对人鼻咽癌CNE2细胞增殖、侵袭、迁移能力的影响[J]. 国际肿瘤学杂志, 2018, 45(8): 453-459.
[13]	刘文斌,高妮娜. miR-210在乳腺癌组织中表达的临床意义及其对三阴性乳腺癌细胞恶性行为的影响[J]. 国际肿瘤学杂志, 2018, 45(8): 525-530.
[14]	董海燕,庞晓燕,窦磊,李丰鑫,田东立,张颐. 肿瘤细胞来源的外泌体在肿瘤转移中的作用[J]. 国际肿瘤学杂志, 2018, 45(7): 427-431.
[15]	吴迪，刘芳，余艳丽，卢蓉，张伟. 大蒜素抑制人类多发性骨髓瘤细胞增殖和侵袭能力的实验研究[J]. 国际肿瘤学杂志, 2018, 45(6): 325-330.